Conciseness

The body is dense and mostly earns its tokens (executable commands, a compact threshold table, a script reference table), but the Overview paragraph explains domain background Claude already knows ('ADMET... is one of the most critical stages in the drug discovery pipeline. Poor pharmacokinetic and toxicity properties are responsible for roughly 40% of clinical trial failures'), and workflow #3 is a pointer back to workflow #1 rather than real content. Minor instances of over-explanation that could be trimmed, matching the score-4 anchor; not the 'several padded sections' of score 3.

Actionability

Every workflow gives copy-paste-ready commands with realistic inputs (a real SMILES string, CSV files), flags, output formats, and concrete CLI invocations, plus a threshold table for interpreting results. This matches the score-5 anchor 'fully executable; copy-paste ready code or commands; specific examples cover the common cases'.

Workflow Clarity

The five workflows are clearly sequenced and each is a single unambiguous command with input/output examples, so sequence is not the issue; what's missing are validation checkpoints (e.g., 'verify SMILES parse before batch runs' or checking row counts of CSV output). This matches the score-4 anchor 'clear sequence with most checkpoints present; minor validation gaps' — these are read-only predictions, not destructive or batch-mutating operations, so the hard cap at 3 does not apply.

Progressive Disclosure

The body itself is well organized with clear sections, but the bundle contains a 409-line references/endpoints_guide.md that is never mentioned or linked anywhere in SKILL.md — a substantial reference resource that is completely un-signaled and undiscoverable from the skill. Per the guideline to score against the actual bundle structure, this matches the score-3 anchor 'references present but not clearly signaled', and is not score 4 because navigation to the main reference file is entirely absent, not merely imperfect.

Specificity

The description enumerates many concrete endpoints across pharmacokinetics ('Caco-2, PPB, clearance, CYP'), toxicity ('hERG, AMES, DILI'), and drug-likeness ('Lipinski, QED'), plus the implementation stack ('using RDKit descriptors and TDC models'). This matches the anchor 'lists multiple specific concrete actions; comprehensive coverage'; there is no vague filler.

Completeness

The 'what' is clear and comprehensive (full endpoint panel with named models), but there is no 'Use when...' clause or equivalent explicit trigger guidance ('for drug candidates' is scope, not a trigger). Per the judging guidelines, a missing 'Use when' clause caps completeness at 3.

Trigger Term Quality

Natural terms a medicinal chemist would say are present ('ADMET property prediction', 'drug candidates', 'toxicity', 'hERG', 'AMES', 'Lipinski', 'QED'), but a few common variations are missing (e.g., 'drug discovery', 'BBB', 'solubility', 'PAINS'). Good coverage with a few natural terms missing, matching the score-4 anchor.

Distinctiveness Conflict Risk

ADMET prediction with endpoint names like hERG, AMES, DILI, and QED is a clear, well-defined niche with distinct triggers, but the description sits in the chemistry category and shares implementation terms ('RDKit descriptors', 'TDC') with closely related cheminformatics skills, giving minor overlap risk — matching the 'mostly distinct; minor overlap risk' anchor rather than the minimal-conflict anchor above.